Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis

BACKGROUND: The survival of patients with metastatic colorectal cancer (mCRC) could be improved with exposure to three active drugs, irinotecan, fluorouracil/leucovorin, and oxaliplatin, irrespective of their sequence. However, only 50%–80% of patients can be exposed to all the three drugs in a sequ...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Wei, Kuang, Meng, Gong, Yang, Cao, Chunxiang, Chen, Jinfei, Tang, Cuiju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976920/
https://www.ncbi.nlm.nih.gov/pubmed/27536147
http://dx.doi.org/10.2147/OTT.S104981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4976920/
https://www.ncbi.nlm.nih.gov/pubmed/27536147
http://dx.doi.org/10.2147/OTT.S104981

Ejemplares similares